For Immediate Release
Contact: info@globalcancertechnology.com
San Diego, CA – July 30, 2025 – Global Cancer Technology (GCT) is excited to announce new
preclinical data demonstrating significant synergy between its proprietary PI3K inhibitor, GCT-
007, and tamoxifen in pre-clinical models of tamoxifen-resistant breast cancer. The study was
conducted using the TC11 mouse model by Dr. Rachel Steinmetz under the direction of Dr. Traci
Lyons at the University of Colorado Anschutz Medical Campus.
“We continue to accumulate compelling evidence of GCT-007’s potential in breast cancer as a
combination therapy,” said Karen Newell Rogers, Chief Scientific Advisor at Global Cancer
Technology. “These results support further preclinical investigation of GCT-007 as a combination
therapy for patients who no longer respond to tamoxifen.”
John Clark, CEO of Global Cancer Technology, added, “We are encouraged by the growing body
of preclinical data showing the efficacy of GCT-007. Collaborating with Dr. Lyons and her team
at the University of Colorado Anschutz—one of the nation’s premier cancer research
institutions—is instrumental in advancing our breast cancer program.”
Dr. Traci Lyons, a leading researcher in breast cancer biology, commented, “We are impressed by
the performance of GCT-007 in our studies and look forward to conducting additional research.”
———————————————————————————————————————
Forward-Looking Statements Disclaimer
Statements in this news release may contain forward-looking statements within the meaning of
Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Such statements involve various risks and uncertainties, some of which may be
discussed in the Company’s most recent shareholder letter. There is no assurance that any new
products can be cleared for sale by the FDA or successfully commercialized.
